+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neuroblastoma (Oncology) - Drugs in Development, 2021

  • PDF Icon

    Report

  • 1265 Pages
  • October 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5473098
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Drugs In Development, 2021, provides an overview of the Neuroblastoma (Oncology) pipeline landscape. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights


This pipeline guide provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 40, 23, 5, 54, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 6, 4, 1, 15 and 1 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology)
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Neuroblastoma - Overview
  • Neuroblastoma - Therapeutics Development
  • Neuroblastoma - Therapeutics Assessment
  • Neuroblastoma - Companies Involved in Therapeutics Development
  • Neuroblastoma - Drug Profiles
  • Neuroblastoma - Dormant Projects
  • Neuroblastoma - Discontinued Products
  • Neuroblastoma - Product Development Milestones

Appendix
List of Tables
  • Number of Products under Development for Neuroblastoma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, 2021
  • Neuroblastoma - Pipeline by Actuate Therapeutics Inc, 2021
  • Neuroblastoma - Pipeline by ADC Therapeutics SA, 2021
  • Neuroblastoma - Pipeline by Adicet Bio Inc, 2021
  • Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, 2021
  • Neuroblastoma - Pipeline by Advenchen Laboratories LLC, 2021
  • Neuroblastoma - Pipeline by Alissa Pharma, 2021
  • Neuroblastoma - Pipeline by APEIRON Biologics AG, 2021
  • Neuroblastoma - Pipeline by Aptorum Group Ltd, 2021
  • Neuroblastoma - Pipeline by AstraZeneca Plc, 2021
  • Neuroblastoma - Pipeline by AUM Biosciences Pte Ltd, 2021
  • Neuroblastoma - Pipeline by Autolus Therapeutics Plc, 2021
  • Neuroblastoma - Pipeline by Bayer AG, 2021
  • Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, 2021
  • Neuroblastoma - Pipeline by Bio-Cancer Treatment International Ltd, 2021
  • Neuroblastoma - Pipeline by Biocad, 2021
  • Neuroblastoma - Pipeline by BioEclipse Therapeutics Inc, 2021
  • Neuroblastoma - Pipeline by Biogenera SpA, 2021
  • Neuroblastoma - Pipeline by BioLineRx Ltd, 2021
  • Neuroblastoma - Pipeline by Biosceptre International Ltd, 2021
  • Neuroblastoma - Pipeline by BioVec Pharma Inc, 2021
  • Neuroblastoma - Pipeline by San Rocco Therapeutics LLC, 2021
  • Neuroblastoma - Pipeline by Sapience Therapeutics Inc, 2021
  • Neuroblastoma - Pipeline by SciTech Development LLC, 2021
  • Neuroblastoma - Pipeline by Secura Bio Inc, 2021
  • Neuroblastoma - Pipeline by Seneca Therapeutics Inc, 2021
  • Neuroblastoma - Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2021
  • Neuroblastoma - Pipeline by Shionogi & Co Ltd, 2021
  • Neuroblastoma - Pipeline by SignalRx Pharmaceuticals Inc, 2021
  • Neuroblastoma - Pipeline by Sinobioway Cell Therapy Co Ltd, 2021
  • Neuroblastoma - Pipeline by SMTPH Ltd, 2021
  • Neuroblastoma - Pipeline by Sorrento Therapeutics Inc, 2021
  • Neuroblastoma - Pipeline by Statera BioPharma Inc, 2021
  • Neuroblastoma - Pipeline by Tactiva Therapeutics LLC, 2021
  • Neuroblastoma - Dormant Projects, 2021
  • Neuroblastoma - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Neuroblastoma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Ability Pharmaceuticals SL
  • Actuate Therapeutics Inc
  • ADC Therapeutics SA
  • Adicet Bio Inc
  • Advanced Accelerator Applications SA
  • Advenchen Laboratories LLC
  • Alissa Pharma
  • APEIRON Biologics AG
  • Aptorum Group Ltd
  • AstraZeneca Plc
  • AUM Biosciences Pte Ltd
  • Autolus Therapeutics Plc
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • Bio-Cancer Treatment International Ltd
  • Biocad
  • BioEclipse Therapeutics Inc
  • Biogenera SpA
  • BioLineRx Ltd
  • Biosceptre International Ltd
  • BioVec Pharma Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Cancer Prevention Pharmaceuticals Inc
  • Cebiotex SL
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Chiome Bioscience Inc
  • Clarity Pharmaceuticals Pty Ltd
  • Collaborations Pharmaceuticals Inc
  • CorMedix Inc
  • Curis Inc
  • Cyclacel Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • DEKK-TEC Inc
  • Eli Lilly and Co
  • Epigene Therapeutics Inc
  • Epizyme Inc
  • Expression Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • GAiA BioMedicine Inc
  • Gibson Oncology LLC
  • GlaxoSmithKline Plc
  • Hebei Senlang Biotechnology Co Ltd
  • Helixmith Co Ltd
  • HRAIN Biotechnology Co Ltd
  • Innovent Biologics Inc
  • Invenra Inc
  • Ipsen SA
  • Jubilant DraxImage Inc
  • KC Pharma LLC
  • Kuur Therapeutics Ltd
  • Lantheus Holdings Inc
  • Lead Discovery Center GmbH
  • LegoChem Biosciences Inc
  • MacroGenics Inc
  • MAIA Biotechnology Inc
  • Mana Therapeutics Inc
  • MediaPharma SRL
  • Merck & Co Inc
  • Nanjing CART Medical Technology Co Ltd
  • Nanogenics Ltd
  • NanoPharmaceuticals LLC
  • Nektar Therapeutics
  • Novartis AG
  • Nurix Therapeutics Inc
  • OBI Pharma Inc
  • OGD2 Pharma SAS
  • Oncolys BioPharma Inc
  • Onconova Therapeutics Inc
  • OncoTherapy Science Inc
  • Ono Pharmaceutical Co Ltd
  • Open Therapeutics LLC
  • Orphelia Pharma SAS
  • PEEL Therapeutics Inc
  • PersonGen Biomedicine Suzhou Co Ltd
  • Pfizer Inc
  • Progenics Pharmaceuticals Inc
  • Provectus Biopharmaceuticals Inc
  • PYC Therapeutics Ltd
  • Qualigen Therapeutics Inc
  • Recombio SL
  • RedHill Biopharma Ltd
  • Ribomic Inc
  • Rophibio Inc
  • San Rocco Therapeutics LLC
  • Sapience Therapeutics Inc
  • SciTech Development LLC
  • Secura Bio Inc
  • Seneca Therapeutics Inc
  • Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • Shionogi & Co Ltd
  • SignalRx Pharmaceuticals Inc
  • Sinobioway Cell Therapy Co Ltd
  • SMTPH Ltd
  • Sorrento Therapeutics Inc
  • Statera BioPharma Inc
  • Tactiva Therapeutics LLC
  • TheraBiologics Inc
  • Tmunity Therapeutics Inc
  • Toko Pharmaceutical Industries Co Ltd
  • Transtarget Inc
  • Trellis Bioscience Inc
  • TroBio Therapeutics Pty Ltd
  • UGISense AG
  • Xcovery Holding Co LLC
  • Y-mAbs Therapeutics Inc
  • ZIOPHARM Oncology Inc